分子量:26.7 kDa

纯度:>95% as determined by SDS-PAGE.

内毒素:Less than 1.0 EU per μg of the Human B7-2, His Tag by the LAL method.

Buffer:PBS, pH7.4

生物活性:Measured by its binding ability in a functional ELISA. 
Immobilized Human B7-2, His Tag (Cat# CD6-H5223) at 2μg/mL (100 l/well),can bind Human CD28, Fc Tag (Cat# CD8-H5257) with a linear of 0.01-5 μg/mL.

产品特性:Human B7-2, His Tag is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 26.7 kDa. The predicted N-terminus is Leu 20. The reducing (R) protein migrates as 43-60 kDa in SDS-PAGE  due to glycosylation.

产品背景:Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.